Cargando…
A comprehensive approach to identify approved drugs and treatments for repositioning as therapies for systemic lupus erythematosus
Autores principales: | Grammer, Amrie C, Ryals, Matthew, Lipsky, Peter E |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4179589/ http://dx.doi.org/10.1186/ar4667 |
Ejemplares similares
-
B cell abnormalities in systemic lupus erythematosus
por: Grammer, Amrie C, et al.
Publicado: (2003) -
Development of targeted biologics for systemic lupus erythematosus
por: Lipsky, Peter E
Publicado: (2012) -
The Impact of Protein Acetylation/Deacetylation on Systemic Lupus Erythematosus
por: Ren, Jingjing, et al.
Publicado: (2018) -
Molecular Characterization of Circulating Plasma Cells in Patients with Active Systemic Lupus Erythematosus
por: Lugar, Patricia L., et al.
Publicado: (2012) -
Gene expression analysis delineates the potential roles of multiple interferons in systemic lupus erythematosus
por: Catalina, Michelle D., et al.
Publicado: (2019)